



ERJer European Respiratory Journal Eur Respir J 0903-19361399-3003 European Respiratory Society 10.1183/13993003.01398-2020 ERJ-01398-2020 AGORA RESEARCH LETTER

Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases M. TADOLINI ET AL.
RESEARCH LETTER Active tuberculosis, sequelae and COVID-19 co-infection



SHAREABLE PDF

Tadolini Marina^{1,44}, Codecasa Luigi Ruffo^{2,44}, García-García José-María³,
Blanc François-Xavier⁴, Borisov Sergey⁵, Alffenaar Jan-Willem^{6,7,8}, Andréjak Claire⁹,
Bachez Pierre¹⁰, Bart Pierre-Alexandre¹¹, Belilovski Evgeny⁵, Cardoso-
Landivar José¹², Centis Rosella¹³, D'Ambrosio Lia¹⁴, Luiza De Souza-Galvão María¹²,
Dominguez-Castellano Angel¹⁵, Dourmane Samir¹⁶, Fréchet Jachym Mathilde¹⁷,
Froissart Antoine¹⁸, Giacomet Vania¹⁹, Goletti Delia²⁰, Grard Soazic²¹, Gualano Gina²²,
Izadifar Armine²³, Le Du Damien¹⁷, Marín Royo Margarita²⁴, Mazza-Stalder Jesica²⁵,
Mottallaria²⁶, Ong Catherine Wei Min^{27,28}, Palmieri Fabrizio²², Rivière Frédéric²⁹,
Rodrigo Teresa³, Silva Denise Rossato³⁰, Sánchez-Montalvá Adrián^{31,32,33},
Saporiti Matteo², Scarpellini Paolo³⁴, Schlemmer Frédéric³⁵, Spanevello Antonio^{36,37},
Sumarokova Elena⁵, Tabernero Eva³⁸, Tambyah Paul Anantharajah^{27,28},
Tiberi Simon^{39,40}, Torre Alessandro⁴¹, Visca Dina^{36,37}, Zabaleta Murguiondo Miguel⁴²,
Sotgiu Giovanni⁴³, Migliori Giovanni Battista¹³,

¹Unit of Infectious Diseases, Dept of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy. ²TB Reference Centre, Villa Marelli Institute, Niguarda Hospital, Milan, Italy.

³Tuberculosis Research Programme (PII-TB), SEPAR, Barcelona, Spain. ⁴Centre Hospitalier Universitaire, Nantes, France. ⁵Moscow Research and Clinical Center for TB Control, Moscow, Russian Federation. ⁶The University of Sydney, Sydney Pharmacy School, Sydney, Australia. ⁷Westmead Hospital, Sydney, Australia.

⁸Marie Bashir Institute of Infectious Diseases and Biosecurity, University of Sydney, Sydney, Australia.

⁹Service de Pneumologie CHU AMIENS PICARDIE, France AND UR Université de Picardie Jules Verne, Amiens, France. ¹⁰Service de Pneumologie, Clinique Saint Luc, Bouge, Belgium. ¹¹Dept of Internal Medicine, Lausanne University, Lausanne, Switzerland. ¹²Servicio Neumología, Vall D'Hebron University Hospital, Barcelona, Spain. ¹³Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy. ¹⁴Public Health Consulting Group, Lugano, Switzerland. ¹⁵Servicio de Enfermedades Infecciosas y Microbiología, Hospital Virgen Macarena, Sevilla, Spain. ¹⁶Service de Pneumologie, Groupe hospitalier sud île de France (GHSIF), Melun, France. ¹⁷Centre Hospitalier de Bligny, Briis Sous Forges, France. ¹⁸Service de Médecine interne, CHI de Crétel, Crétel, France. ¹⁹Pediatric Infectious Diseases Unit, Dept of Biomedical and Clinical Sciences, L. Sacco Hospital, University of Milan, Milan, Italy. ²⁰Translational Research Unit, National Institute for Infectious Diseases 'L. Spallanzani', IRCCS, Rome, Italy. ²¹Centre de Lutte Antituberculeuse (CLAT 38), Grenoble, France. ²²Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases 'L. Spallanzani', IRCCS, Rome, Italy. ²³Hôpital Européen de Paris La Roseraie, Aubervilliers, France. ²⁴Servicio Neumología, Hospital General Universitario de Castellón, Castelló, Spain. ²⁵Pulmonary Division, Lausanne University Hospital CHUV, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. ²⁶Dipartimento di Scienze Mediche, Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italia. ²⁷Dept of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. ²⁸Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore. ²⁹Hôpital d'Instruction des Armées (HIA) Percy, Clamart, France. ³⁰Faculdade de Medicina, Universidade Federal do Rio Grande do Sul – UFRGS, Porto Alegre, Brazil. ³¹Infectious Diseases Dept, International Health and Tuberculosis Unit, Vall d'Hebron University Hospital, Barcelona, Spain. ³²Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain. ³³Grupo de Estudio de Infecciones por Micobacterias (GEIM), Spanish Society of Infectious Diseases (SEIMC), Spain. ³⁴Unit of Infectious Diseases, Università Vita e Salute, San Raffaele Hospital, Milan, Italy. ³⁵Hôpitaux Universitaires Henri Mondor, AP-HP, Crétel, France. ³⁶Division of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS, Tradate, Italy. ³⁷Dept of Medicine and Surgery, Respiratory Diseases, University of Insubria, Tradate, Italy. ³⁸Servicio Neumología, Hospital de Cruces, Bilbao, Spain. ³⁹Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. ⁴⁰Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK. ⁴¹Dept of Infectious Diseases, University of Milan, L. Sacco Hospital, Milan, Italy. ⁴²Servicio Neumología Hospital Universitario Marqués de Valdecilla, Santander, Spain. ⁴³Clinical Epidemiology and Medical Statistics Unit, Dept of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy. ⁴⁴Co-first authors.

Correspondence: Giovanni Battista Migliori, Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Via Roncaccio 16, Tradate, Varese, 21049, Italy. E-mail: giovannibattista.migliori@icsmaugeri.it 202020205025042020100520202020

To the Editor:

Copyright ©ERS 2020.. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) pandemic has attracted interest because of its global rapid spread, clinical severity, high mortality rate and capacity to overwhelm healthcare systems [1, 2]. SARS-CoV-2 transmission occurs mainly through droplets, although surface contamination contributes and debate continues on aerosol transmission [3–5].